Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright » 11:03
08/11/20
08/11
11:03
08/11/20
11:03
LGND

Ligand

$116.28 /

-2.2 (-1.86%)

, PFNX

Pfenex

$12.75 /

+5.07 (+66.02%)

, JAZZ

Jazz Pharmaceuticals

$125.31 /

-1.03 (-0.82%)

, MRK

Merck

$81.11 /

+0.2 (+0.25%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis notes that Ligand (LGND) has announced that it was acquiring Pfenex (PFNX), which is a platform technology company with a proprietary protein expression system. The analyst believes this transaction fits well with Ligand's ever growing portfolio as it could work well with the OmniAb platform, is already validated with existing partnerships with Jazz Pharmaceutical (JAZZ) and Merck (MRK), and continued delivery of partners over the long-term. Pantginis has a Buy rating and a $229 price target on Ligand's shares.

ShowHide Related Items >><<
PFNX Pfenex
$12.75 /

+5.07 (+66.02%)

MRK Merck
$81.11 /

+0.2 (+0.25%)

LGND Ligand
$116.28 /

-2.2 (-1.86%)

JAZZ Jazz Pharmaceuticals
$125.31 /

-1.03 (-0.82%)

LGND Ligand
$116.28 /

-2.2 (-1.86%)

06:25 Today JMP Securities
Pfenex cut to Market Perform at JMP Securities on Ligand acquisition
08/04/20 Roth Capital
Ligand price target raised to $190 from $180 at Roth Capital
08/04/20 Barclays
Ligand price target raised to $145 from $134 at Barclays
07/14/20 Benchmark
Ligand price target raised to $155 from $135 at Benchmark
PFNX Pfenex
$12.75 /

+5.07 (+66.02%)

05:49 Today JMP Securities
Pfenex downgraded to Market Perform from Outperform at JMP Securities
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/15/20 Oppenheimer
Pfenex price target raised to $15 from $10 at Oppenheimer
JAZZ Jazz Pharmaceuticals
$125.31 /

-1.03 (-0.82%)

08/06/20 Morgan Stanley
Morgan Stanley upgrades Jazz to Overweight on re-evaluation of Xyrem franchise
08/06/20 Morgan Stanley
Jazz Pharmaceuticals upgraded to Overweight from Equal Weight at Morgan Stanley
07/30/20 Oppenheimer
Avadel Pharmaceuticals initiated with an Outperform at Oppenheimer
07/28/20 Wolfe Research
Jazz Pharmaceuticals upgraded to Outperform from Peer Perform at Wolfe Research
MRK Merck
$81.11 /

+0.2 (+0.25%)

08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
PFNX Pfenex
$12.75 /

+5.07 (+66.02%)

MRK Merck
$81.11 /

+0.2 (+0.25%)

LGND Ligand
$116.28 /

-2.2 (-1.86%)

JAZZ Jazz Pharmaceuticals
$125.31 /

-1.03 (-0.82%)

MRK Merck
$81.11 /

+0.2 (+0.25%)

PFNX Pfenex
$12.75 /

+5.07 (+66.02%)

MRK Merck
$81.11 /

+0.2 (+0.25%)

LGND Ligand
$116.28 /

-2.2 (-1.86%)

JAZZ Jazz Pharmaceuticals
$125.31 /

-1.03 (-0.82%)

MRK Merck
$81.11 /

+0.2 (+0.25%)

Thursday
Periodicals
Trump to order government to buy certain drugs from U.S., USA Today says » 10:12
08/06/20
08/06
10:12
08/06/20
10:12
JNJ

Johnson & Johnson

$148.29 /

-0.1 (-0.07%)

, LLY

Eli Lilly

$154.75 /

+0.36 (+0.23%)

, MRK

Merck

$81.48 /

-0.13 (-0.16%)

, PFE

Pfizer

$38.73 /

+0.28 (+0.73%)

, SNY

Sanofi

$51.41 /

-0.27 (-0.52%)

, AZN

AstraZeneca

$56.22 /

+0.3 (+0.54%)

, GSK

GlaxoSmithKline

$41.04 /

-0.17 (-0.41%)

, NVS

Novartis

$83.51 /

+0.07 (+0.08%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$61.67 /

+1.98 (+3.32%)

President Donald Trump…

President Donald Trump will sign an executive order mandating the federal government to buy certain drugs from U.S. manufacturers rather than foreign companies, USA Today's Michael Collins reports, citing officials. The order, which will be signed at Whirlpool's (WHR) manufacturing facility in Ohio, requires the government to develop a list of "essential" medicines and purchase them as well as other medical supplies from the U.S. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
MRK Merck
$81.48 /

-0.13 (-0.16%)

08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$38.73 /

+0.28 (+0.73%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
NVS Novartis
$83.51 /

+0.07 (+0.08%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

Options
Unusually active option classes on open August 6th » 09:40
08/06/20
08/06
09:40
08/06/20
09:40
BHC

Bausch Health

$19.45 /

+ (+0.00%)

, COMM

CommScope

$9.49 /

+ (+0.00%)

, BMY

Bristol-Myers

$59.69 /

+ (+0.00%)

, MRVL

Marvell

$37.79 /

+ (+0.00%)

, KNDI

Kandi Technologies

$8.66 /

+ (+0.00%)

, AAL

American Airlines

$12.55 /

-0.01 (-0.08%)

, SAVE

Spirit Airlines

$17.16 /

+ (+0.00%)

, FXI

iShares China Large-Cap ETF

$42.81 /

+ (+0.00%)

, MRK

Merck

$81.61 /

+ (+0.00%)

, SQ

Square

$146.46 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Bausch Health (BHC), CommScope (COMM), Bristol Myers Squibb (BMY), Marvell (MRVL), Kandi Technologies (KNDI), American Airlines (AAL), Spirit Airlines (SAVE), iShares China Large Cap ETF (FXI), Merck (MRK), and Square (SQ).

ShowHide Related Items >><<
SQ Square
$146.46 /

+ (+0.00%)

SAVE Spirit Airlines
$17.16 /

+ (+0.00%)

MRVL Marvell
$37.79 /

+ (+0.00%)

MRK Merck
$81.61 /

+ (+0.00%)

KNDI Kandi Technologies
$8.66 /

+ (+0.00%)

COMM CommScope
$9.49 /

+ (+0.00%)

BMY Bristol-Myers
$59.69 /

+ (+0.00%)

BHC Bausch Health
$19.45 /

+ (+0.00%)

AAL American Airlines
$12.55 /

-0.01 (-0.08%)

BHC Bausch Health
$19.45 /

+ (+0.00%)

06/17/20 H.C. Wainwright
Bausch Health price target raised to $64 from $50 at H.C. Wainwright
06/03/20 Jefferies
Duobrii could become a key revenue driver for Bausch Health, says Jefferies
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Bausch Health initiated with a Buy at Citi
COMM CommScope
$9.49 /

+ (+0.00%)

07/28/20 Raymond James
Corning results provide read-through to optical names, says Raymond James
07/24/20 Wolfe Research
CommScope initiated with an Outperform at Wolfe Research
07/07/20 Raymond James
CommScope downgraded to Market Perform at Raymond James on valuation
07/07/20 Raymond James
CommScope downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$59.69 /

+ (+0.00%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
MRVL Marvell
$37.79 /

+ (+0.00%)

07/21/20 Piper Sandler
Marvell price target raised to $42 from $35 at Piper Sandler
07/15/20
Fly Intel: Top five analyst downgrades
07/15/20 Wells Fargo
Marvell downgraded to Equal Weight after recent rally at Wells Fargo
07/15/20 Wells Fargo
Marvell downgraded to Equal Weight from Overweight at Wells Fargo
KNDI Kandi Technologies
$8.66 /

+ (+0.00%)

AAL American Airlines
$12.55 /

-0.01 (-0.08%)

07/28/20 Citi
Citi cuts American Airlines target to $11, opens negative catalyst watch
07/27/20
Fly Intel: Top five analyst upgrades
07/27/20 Raymond James
American Airlines upgraded at Raymond James on balanced risk-reward
07/27/20 Raymond James
American Airlines upgraded to Market Perform from Underperform at Raymond James
SAVE Spirit Airlines
$17.16 /

+ (+0.00%)

07/09/20 Citi
Citi sees expectations for corporate travel rebound all but evaporating
06/29/20 Goldman Sachs
Spirit Airlines price target raised to $20 from $15 at Goldman Sachs
06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
Spirit Airlines initiated with a Buy at Seaport Global
FXI iShares China Large-Cap ETF
$42.81 /

+ (+0.00%)

MRK Merck
$81.61 /

+ (+0.00%)

08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
SQ Square
$146.46 /

+ (+0.00%)

08/06/20 Susquehanna
Square price target raised to $180 from $145 at Susquehanna
08/06/20 Credit Suisse
Square price target raised to $170 from $80 at Credit Suisse
08/06/20 Wells Fargo
Square price target raised to $175 from $75 at Wells Fargo
08/06/20 Compass Point
Compass Point upgrades Square to Neutral on more resilience than expected
SQ Square
$146.46 /

+ (+0.00%)

SAVE Spirit Airlines
$17.16 /

+ (+0.00%)

MRVL Marvell
$37.79 /

+ (+0.00%)

MRK Merck
$81.61 /

+ (+0.00%)

KNDI Kandi Technologies
$8.66 /

+ (+0.00%)

COMM CommScope
$9.49 /

+ (+0.00%)

BMY Bristol-Myers
$59.69 /

+ (+0.00%)

BHC Bausch Health
$19.45 /

+ (+0.00%)

AAL American Airlines
$12.55 /

-0.01 (-0.08%)

  • 23
    Jun
  • 08
    May
SQ Square
$146.46 /

+ (+0.00%)

SAVE Spirit Airlines
$17.16 /

+ (+0.00%)

MRK Merck
$81.61 /

+ (+0.00%)

BMY Bristol-Myers
$59.69 /

+ (+0.00%)

AAL American Airlines
$12.55 /

-0.01 (-0.08%)

SQ Square
$146.46 /

+ (+0.00%)

SAVE Spirit Airlines
$17.16 /

+ (+0.00%)

MRVL Marvell
$37.79 /

+ (+0.00%)

MRK Merck
$81.61 /

+ (+0.00%)

KNDI Kandi Technologies
$8.66 /

+ (+0.00%)

COMM CommScope
$9.49 /

+ (+0.00%)

BMY Bristol-Myers
$59.69 /

+ (+0.00%)

BHC Bausch Health
$19.45 /

+ (+0.00%)

AAL American Airlines
$12.55 /

-0.01 (-0.08%)

SQ Square
$146.46 /

+ (+0.00%)

SAVE Spirit Airlines
$17.16 /

+ (+0.00%)

MRVL Marvell
$37.79 /

+ (+0.00%)

MRK Merck
$81.61 /

+ (+0.00%)

KNDI Kandi Technologies
$8.66 /

+ (+0.00%)

FXI iShares China Large-Cap ETF
$42.81 /

+ (+0.00%)

COMM CommScope
$9.49 /

+ (+0.00%)

BMY Bristol-Myers
$59.69 /

+ (+0.00%)

BHC Bausch Health
$19.45 /

+ (+0.00%)

AAL American Airlines
$12.55 /

-0.01 (-0.08%)

FXI iShares China Large-Cap ETF
$42.81 /

+ (+0.00%)

Wednesday
Options
Merck call volume above normal and directionally bullish » 10:45
08/05/20
08/05
10:45
08/05/20
10:45
MRK

Merck

$81.49 /

-0.18 (-0.22%)

Bullish option flow…

Bullish option flow detected in Merck with 17,625 calls trading, 3x expected, and implied vol increasing almost 2 points to 25.86%. Sep-20 82.5 calls and Aug-20 82.5 calls are the most active options, with total volume in those strikes near 12,100 contracts. The Put/Call Ratio is 0.11. Earnings are expected on October 27th.

ShowHide Related Items >><<
MRK Merck
$81.49 /

-0.18 (-0.22%)

MRK Merck
$81.49 /

-0.18 (-0.22%)

08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
MRK Merck
$81.49 /

-0.18 (-0.22%)

MRK Merck
$81.49 /

-0.18 (-0.22%)

MRK Merck
$81.49 /

-0.18 (-0.22%)

MRK Merck
$81.49 /

-0.18 (-0.22%)

Options
Unusually active option classes on open August 5th » 09:40
08/05/20
08/05
09:40
08/05/20
09:40
DD

DuPont

$53.15 /

+ (+0.00%)

, WLL

Whiting Petroleum

$1.07 /

+ (+0.00%)

, OAS

Oasis Petroleum

$0.68 /

+ (+0.00%)

, WRTC

Wrap Technologies

$9.76 /

+ (+0.00%)

, CVS

CVS Health

$64.99 /

+ (+0.00%)

, USO

United States Oil Fund

$29.77 /

+ (+0.00%)

, MVIS

MicroVision

$2.54 /

+ (+0.00%)

, HUYA

Huya

$25.10 /

+ (+0.00%)

, MRK

Merck

$81.67 /

+ (+0.00%)

, DBX

Dropbox

$23.22 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: DuPont de Nemours (DD), Whiting Petroleum (WLL), Oasis Petroleum (OAS), Wrap Technologies (WRTC), CVS Health (CVS), United States Oil Fund (USO), Microvision (MVIS), HUYA (HUYA), Merck (MRK), and Dropbox (DBX).

ShowHide Related Items >><<
WRTC Wrap Technologies
$9.76 /

+ (+0.00%)

WLL Whiting Petroleum
$1.07 /

+ (+0.00%)

USO United States Oil Fund
$29.77 /

+ (+0.00%)

OAS Oasis Petroleum
$0.68 /

+ (+0.00%)

MVIS MicroVision
$2.54 /

+ (+0.00%)

MRK Merck
$81.67 /

+ (+0.00%)

HUYA Huya
$25.10 /

+ (+0.00%)

DD DuPont
$53.15 /

+ (+0.00%)

DBX Dropbox
$23.22 /

+ (+0.00%)

CVS CVS Health
$64.99 /

+ (+0.00%)

DD DuPont
$53.15 /

+ (+0.00%)

08/04/20 Deutsche Bank
DuPont price target raised to $65 from $62 at Deutsche Bank
08/03/20
Fly Intel: Top five analyst downgrades
08/03/20 Stephens
DuPont downgraded to Equal Weight from Overweight at Stephens
08/03/20 Stephens
DuPont downgraded to Equal Weight from Overweight at Stephens
WLL Whiting Petroleum
$1.07 /

+ (+0.00%)

04/03/20 Wells Fargo
Wells Fargo says oil markets heading into eye of 'perfect storm' in Q2
03/31/20 Stifel
Whiting Petroleum downgraded to Sell from Hold at Stifel
03/25/20 JPMorgan
Whiting Petroleum downgraded to Underweight from Neutral at JPMorgan
03/24/20 Barclays
Whiting Petroleum downgraded to Underweight from Equal Weight at Barclays
OAS Oasis Petroleum
$0.68 /

+ (+0.00%)

06/09/20 Citi
Oasis Petroleum downgraded to Sell from Neutral at Citi
06/09/20 Citi
Oasis Petroleum downgraded to Sell from Neutral at Citi
05/01/20 Tudor Pickering
Oasis Petroleum downgraded to Sell from Hold at Tudor Pickering
WRTC Wrap Technologies
$9.76 /

+ (+0.00%)

07/31/20 Ladenburg
Wrap Technologies price target raised to $14 from $9.75 at Ladenburg
07/06/20 Northland
Wrap Technologies downgraded to Market Perform from Outperform at Northland
03/24/20 Northland
Wrap Technologies upgraded to Outperform from Market Perform at Northland
01/29/20 Ladenburg
Wrap Technologies initiated with a Buy at Ladenburg
CVS CVS Health
$64.99 /

+ (+0.00%)

07/29/20 RBC Capital
Livongo Health ending re-seller relationship with CVS Health, says RBC Capital
07/01/20 SVB Leerink
CVS Health reinstated with a Market Perform at SVB Leerink
06/01/20 Stephens
Molina Healthcare price target raised to $215 from $202 at Stephens
05/14/20
Fly Intel: Top five analyst upgrades
USO United States Oil Fund
$29.77 /

+ (+0.00%)

MVIS MicroVision
$2.54 /

+ (+0.00%)

05/06/20 Craig-Hallum
MicroVision rise driven by Microsoft speculation, says Craig-Hallum
02/26/20 Craig-Hallum
MicroVision downgraded to Hold from Buy at Craig-Hallum
02/26/20 H.C. Wainwright
MicroVision downgraded to Neutral from Buy at H.C. Wainwright
02/26/20 Ladenburg
Ladenburg downgrades MicroVision to Neutral on lost contract
HUYA Huya
$25.10 /

+ (+0.00%)

07/21/20 JPMorgan
Huya downgraded to Neutral from Overweight at JPMorgan
05/21/20 CLSA
Huya downgraded to Outperform from Buy at CLSA
05/21/20 Credit Suisse
Huya downgraded to Neutral on lack of catalysts at Credit Suisse
05/21/20 Credit Suisse
Huya downgraded to Neutral from Outperform at Credit Suisse
MRK Merck
$81.67 /

+ (+0.00%)

08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
DBX Dropbox
$23.22 /

+ (+0.00%)

07/31/20
Fly Intel: Top five analyst downgrades
07/31/20 BofA
Dropbox downgraded to Neutral from Buy at BofA
07/20/20
Fly Intel: Top five analyst upgrades
07/20/20 Jefferies
Dropbox upgraded to Buy from Hold at Jefferies
WRTC Wrap Technologies
$9.76 /

+ (+0.00%)

WLL Whiting Petroleum
$1.07 /

+ (+0.00%)

OAS Oasis Petroleum
$0.68 /

+ (+0.00%)

MVIS MicroVision
$2.54 /

+ (+0.00%)

MRK Merck
$81.67 /

+ (+0.00%)

HUYA Huya
$25.10 /

+ (+0.00%)

DD DuPont
$53.15 /

+ (+0.00%)

DBX Dropbox
$23.22 /

+ (+0.00%)

CVS CVS Health
$64.99 /

+ (+0.00%)

WRTC Wrap Technologies
$9.76 /

+ (+0.00%)

WLL Whiting Petroleum
$1.07 /

+ (+0.00%)

USO United States Oil Fund
$29.77 /

+ (+0.00%)

OAS Oasis Petroleum
$0.68 /

+ (+0.00%)

MVIS MicroVision
$2.54 /

+ (+0.00%)

MRK Merck
$81.67 /

+ (+0.00%)

DD DuPont
$53.15 /

+ (+0.00%)

DBX Dropbox
$23.22 /

+ (+0.00%)

CVS CVS Health
$64.99 /

+ (+0.00%)

WRTC Wrap Technologies
$9.76 /

+ (+0.00%)

WLL Whiting Petroleum
$1.07 /

+ (+0.00%)

OAS Oasis Petroleum
$0.68 /

+ (+0.00%)

MVIS MicroVision
$2.54 /

+ (+0.00%)

MRK Merck
$81.67 /

+ (+0.00%)

HUYA Huya
$25.10 /

+ (+0.00%)

DD DuPont
$53.15 /

+ (+0.00%)

DBX Dropbox
$23.22 /

+ (+0.00%)

CVS CVS Health
$64.99 /

+ (+0.00%)

WRTC Wrap Technologies
$9.76 /

+ (+0.00%)

WLL Whiting Petroleum
$1.07 /

+ (+0.00%)

USO United States Oil Fund
$29.77 /

+ (+0.00%)

OAS Oasis Petroleum
$0.68 /

+ (+0.00%)

MVIS MicroVision
$2.54 /

+ (+0.00%)

MRK Merck
$81.67 /

+ (+0.00%)

HUYA Huya
$25.10 /

+ (+0.00%)

DD DuPont
$53.15 /

+ (+0.00%)

DBX Dropbox
$23.22 /

+ (+0.00%)

CVS CVS Health
$64.99 /

+ (+0.00%)

USO United States Oil Fund
$29.77 /

+ (+0.00%)

Over a week ago
Recommendations
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler » 15:18
08/04/20
08/04
15:18
08/04/20
15:18
ALT

Altimmune

$28.22 /

+1.06 (+3.90%)

, MRK

Merck

$81.25 /

-1.3 (-1.57%)

Merck (MRK) and Hanmi…

Merck (MRK) and Hanmi Pharma this morning entered into an agreement for Merck to license efinopegdutide, a GLP-1:glucagon agonist, for development in nonalcoholic steatohepatitis, Piper Sandler analyst Yasmeen Rahimi tells investors in a research note. With only a $10M upfront payment for Hanmi's asset, there is a "strong rationale" for Altimmune's (ALT) GLP-1:glucagon agonist ALT-801, which is expected to start Phase 1 testing in Q4, to bring a cleaner gastrointestinal tolerability profile, says the analyst. Large pharma interest in dual GLP-1:glucagon agonists validates the mechanism of action in NASH, and ALT-801's therapeutic has a potentially higher value than efinopegdutide, contends Rahimi. The analyst keeps an Overweight rating on Altimmune with an $80 price target.

ShowHide Related Items >><<
MRK Merck
$81.25 /

-1.3 (-1.57%)

ALT Altimmune
$28.22 /

+1.06 (+3.90%)

ALT Altimmune
$28.22 /

+1.06 (+3.90%)

07/31/20
Fly Intel: Top five analyst initiations
07/30/20 Piper Sandler
Altimmune initiated with an Overweight at Piper Sandler
07/28/20 JMP Securities
Altimmune initiated with an Outperform at JMP Securities
06/01/20 Roth Capital
Altimmune surprises with differentiated T-COVID study, says Roth Capital
MRK Merck
$81.25 /

-1.3 (-1.57%)

08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
MRK Merck
$81.25 /

-1.3 (-1.57%)

ALT Altimmune
$28.22 /

+1.06 (+3.90%)

  • 14
    Jul
MRK Merck
$81.25 /

-1.3 (-1.57%)

MRK Merck
$81.25 /

-1.3 (-1.57%)

ALT Altimmune
$28.22 /

+1.06 (+3.90%)

MRK Merck
$81.25 /

-1.3 (-1.57%)

ALT Altimmune
$28.22 /

+1.06 (+3.90%)

Hot Stocks
Merck, Hanmi Pharmaceutical enter into exclusive licensing agreement » 05:30
08/04/20
08/04
05:30
08/04/20
05:30
MRK

Merck

$82.55 /

+2.29 (+2.85%)

Merck and Hanmi…

Merck and Hanmi Pharmaceutical announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide, formerly HM12525A, Hanmi's investigational once-weekly glucagon-like peptide-1, or GLP-1,/glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis, or NASH. The companies said in a release, "Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercialize efinopegdutide in the United States and globally. Hanmi will receive an upfront payment of $10 million and is eligible to receive milestone payments up to $860 million associated with the development, regulatory approval and commercialization of efinopegdutide, as well as double-digit royalties on sales of approved product. Hanmi retains an option to commercialize efinopegdutide in Korea."

ShowHide Related Items >><<
MRK Merck
$82.55 /

+2.29 (+2.85%)

MRK Merck
$82.55 /

+2.29 (+2.85%)

08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
MRK Merck
$82.55 /

+2.29 (+2.85%)

MRK Merck
$82.55 /

+2.29 (+2.85%)

MRK Merck
$82.55 /

+2.29 (+2.85%)

MRK Merck
$82.55 /

+2.29 (+2.85%)

Upgrade
Fly Intel: Top five analyst upgrades » 10:11
08/03/20
08/03
10:11
08/03/20
10:11
YUM

Yum! Brands

$91.48 /

+0.485 (+0.53%)

, PINS

Pinterest

$36.77 /

+2.475 (+7.22%)

, MRK

Merck

$82.45 /

+2.19 (+2.73%)

, UAA

Under Armour

$10.02 /

-0.465 (-4.44%)

, DNKN

Dunkin' Brands

$68.83 /

+0.14 (+0.20%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Yum! Brands (YUM) upgraded to Buy from Hold at Deutsche Bank with analyst Brian Mullan saying after a sell-off earlier this year and subsequent recovery, the shares are "poised to grind higher again on a more consistent basis moving forward." 2. Pinterest (PINS) upgraded to Buy from Neutral at UBS and to Buy from Hold at Pivotal Research. 3. Merck (MRK) upgraded to Buy from Neutral at Goldman Sachs with analyst Terence Flynn saying his positive outlook on the shares consists of pipeline and balance sheet "optionality." 4. Under Armour (UAA) upgraded to Neutral from Negative at Susquehanna with analyst Sam Poser saying he sees less potential for extreme downside for the stock following its Q2 earnings call. 5. Dunkin' Brands (DNKN) upgraded to Buy from Neutral at BofA with the firm's analyst expecting breakfast and coffee to be negatively impacted by COVID-19 given how morning commutes are being disrupted by higher unemployment and work-from-home trends, but the analyst thinks the brand is taking share from convenience stores given the consumer safety benefits of drive-thrus and it is his expectation that Dunkin' will grow coffee and breakfast share during the pandemic. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
YUM Yum! Brands
$91.48 /

+0.485 (+0.53%)

UAA Under Armour
$10.02 /

-0.465 (-4.44%)

PINS Pinterest
$36.77 /

+2.475 (+7.22%)

MRK Merck
$82.45 /

+2.19 (+2.73%)

DNKN Dunkin' Brands
$68.83 /

+0.14 (+0.20%)

YUM Yum! Brands
$91.48 /

+0.485 (+0.53%)

08/03/20 Deutsche Bank
Deutsche Bank upgrades Yum! to Buy, sees shares grinding higher
08/03/20 Deutsche Bank
Yum! Brands upgraded to Buy from Hold at Deutsche Bank
07/31/20 RBC Capital
Yum! Brands price target raised to $94 from $87 at RBC Capital
06/24/20 MKM Partners
Yum! Brands price target raised to $90 from $75 at MKM Partners
PINS Pinterest
$36.77 /

+2.475 (+7.22%)

08/03/20 Wedbush
Pinterest price target raised to $39 from $31 at Wedbush
08/03/20 DA Davidson
Pinterest price target raised to $28 from $19 at DA Davidson
08/03/20 JPMorgan
Pinterest price target raised to $37 from $26 at JPMorgan
08/03/20 MKM Partners
Pinterest price target raised to $35 from $26 at MKM Partners
MRK Merck
$82.45 /

+2.19 (+2.73%)

08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
UAA Under Armour
$10.02 /

-0.465 (-4.44%)

08/03/20 Susquehanna
Under Armour downside seen limited, Susquehanna upgrades to Neutral
08/03/20 Susquehanna
Under Armour upgraded to Neutral from Negative at Susquehanna
07/28/20 Jefferies
Under Armour 'inquiry matters, but it doesn't matter,' says Jefferies
07/24/20 Deutsche Bank
Under Armour named short-term buy idea at Deutsche Bank
DNKN Dunkin' Brands
$68.83 /

+0.14 (+0.20%)

08/03/20 BofA
Dunkin' Brands upgraded to Buy at BofA on share gain potential
08/03/20 BofA
Dunkin' Brands upgraded to Buy from Neutral at BofA
07/31/20
Fly Intel: Top five analyst upgrades
07/31/20 JPMorgan
Dunkin' Brands upgraded to Overweight from Neutral at JPMorgan
YUM Yum! Brands
$91.48 /

+0.485 (+0.53%)

UAA Under Armour
$10.02 /

-0.465 (-4.44%)

PINS Pinterest
$36.77 /

+2.475 (+7.22%)

MRK Merck
$82.45 /

+2.19 (+2.73%)

DNKN Dunkin' Brands
$68.83 /

+0.14 (+0.20%)

  • 16
    Oct
YUM Yum! Brands
$91.48 /

+0.485 (+0.53%)

UAA Under Armour
$10.02 /

-0.465 (-4.44%)

PINS Pinterest
$36.77 /

+2.475 (+7.22%)

MRK Merck
$82.45 /

+2.19 (+2.73%)

DNKN Dunkin' Brands
$68.83 /

+0.14 (+0.20%)

YUM Yum! Brands
$91.48 /

+0.485 (+0.53%)

UAA Under Armour
$10.02 /

-0.465 (-4.44%)

MRK Merck
$82.45 /

+2.19 (+2.73%)

DNKN Dunkin' Brands
$68.83 /

+0.14 (+0.20%)

YUM Yum! Brands
$91.48 /

+0.485 (+0.53%)

UAA Under Armour
$10.02 /

-0.465 (-4.44%)

PINS Pinterest
$36.77 /

+2.475 (+7.22%)

MRK Merck
$82.45 /

+2.19 (+2.73%)

DNKN Dunkin' Brands
$68.83 /

+0.14 (+0.20%)

On The Fly
Merck, Dunkin' Brands upgrades among today's top calls on Wall Street » 10:08
08/03/20
08/03
10:08
08/03/20
10:08
MRK

Merck

$82.22 /

+1.96 (+2.44%)

, DNKN

Dunkin' Brands

$69.00 /

+0.31 (+0.45%)

, QCOM

Qualcomm

$112.09 /

+6.53 (+6.19%)

, PINS

Pinterest

$36.83 /

+2.54 (+7.41%)

, EXPE

Expedia

$81.16 /

+0.09 (+0.11%)

Check out today's top…

Open Full Text

ShowHide Related Items >><<
QCOM Qualcomm
$112.09 /

+6.53 (+6.19%)

PINS Pinterest
$36.83 /

+2.54 (+7.41%)

MRK Merck
$82.22 /

+1.96 (+2.44%)

EXPE Expedia
$81.16 /

+0.09 (+0.11%)

DNKN Dunkin' Brands
$69.00 /

+0.31 (+0.45%)

MRK Merck
$82.22 /

+1.96 (+2.44%)

08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
DNKN Dunkin' Brands
$69.00 /

+0.31 (+0.45%)

08/03/20 BofA
Dunkin' Brands upgraded to Buy at BofA on share gain potential
08/03/20 BofA
Dunkin' Brands upgraded to Buy from Neutral at BofA
07/31/20
Fly Intel: Top five analyst upgrades
07/31/20 JPMorgan
Dunkin' Brands upgraded to Overweight from Neutral at JPMorgan
QCOM Qualcomm
$112.09 /

+6.53 (+6.19%)

08/03/20 Bernstein
Qualcomm upgraded to Outperform at Bernstein
08/03/20 Bernstein
Qualcomm upgraded to Outperform from Market Perform at Bernstein
07/31/20 Edward Jones
Qualcomm upgraded to Hold on Huawei settlement at Edward Jones
PINS Pinterest
$36.83 /

+2.54 (+7.41%)

08/03/20 Wedbush
Pinterest price target raised to $39 from $31 at Wedbush
08/03/20 DA Davidson
Pinterest price target raised to $28 from $19 at DA Davidson
08/03/20 JPMorgan
Pinterest price target raised to $37 from $26 at JPMorgan
08/03/20 MKM Partners
Pinterest price target raised to $35 from $26 at MKM Partners
EXPE Expedia
$81.16 /

+0.09 (+0.11%)

08/03/20 BTIG
Expedia upgraded to Buy from Neutral at BTIG
08/03/20 BTIG
Expedia upgraded to Buy from Neutral at BTIG
07/31/20 RBC Capital
Expedia price target lowered to $93 from $105 at RBC Capital
07/29/20 Jefferies
Booking Holdings price target raised to $1,600 from $1,300 at Jefferies
QCOM Qualcomm
$112.09 /

+6.53 (+6.19%)

PINS Pinterest
$36.83 /

+2.54 (+7.41%)

MRK Merck
$82.22 /

+1.96 (+2.44%)

EXPE Expedia
$81.16 /

+0.09 (+0.11%)

DNKN Dunkin' Brands
$69.00 /

+0.31 (+0.45%)

  • 16
    Oct
QCOM Qualcomm
$112.09 /

+6.53 (+6.19%)

PINS Pinterest
$36.83 /

+2.54 (+7.41%)

MRK Merck
$82.22 /

+1.96 (+2.44%)

EXPE Expedia
$81.16 /

+0.09 (+0.11%)

DNKN Dunkin' Brands
$69.00 /

+0.31 (+0.45%)

QCOM Qualcomm
$112.09 /

+6.53 (+6.19%)

PINS Pinterest
$36.83 /

+2.54 (+7.41%)

MRK Merck
$82.22 /

+1.96 (+2.44%)

EXPE Expedia
$81.16 /

+0.09 (+0.11%)

DNKN Dunkin' Brands
$69.00 /

+0.31 (+0.45%)

QCOM Qualcomm
$112.09 /

+6.53 (+6.19%)

PINS Pinterest
$36.83 /

+2.54 (+7.41%)

MRK Merck
$82.22 /

+1.96 (+2.44%)

EXPE Expedia
$81.16 /

+0.09 (+0.11%)

DNKN Dunkin' Brands
$69.00 /

+0.31 (+0.45%)

Hot Stocks
Merck Animal Health completes acquisition of worldwide rights to VECOXAN » 06:32
08/03/20
08/03
06:32
08/03/20
06:32
MRK

Merck

$80.26 /

+1.21 (+1.53%)

, ELAN

Elanco

$23.62 /

+1.18 (+5.26%)

Merck Animal Health, a…

Merck Animal Health, a division of Merck & Co. (MRK), announced the completion of its previously announced acquisition of the worldwide rights to VECOXAN, an oral suspension for the prevention of coccidiosis in calves and lambs, from Elanco Animal Health (ELAN).

ShowHide Related Items >><<
MRK Merck
$80.26 /

+1.21 (+1.53%)

ELAN Elanco
$23.62 /

+1.18 (+5.26%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
ELAN Elanco
$23.62 /

+1.18 (+5.26%)

07/27/20 Evercore ISI
Evercore worried after deep dive into Elanco channel inventories
07/27/20 Cleveland Research
Elanco downgraded to Underperform from Neutral at Cleveland Research
06/05/20 Citi
Citi opens 'positive catalyst watch' on Elanco Animal Health
05/15/20 Citi
Elanco price target lowered to $27 from $35 at Citi
MRK Merck
$80.26 /

+1.21 (+1.53%)

ELAN Elanco
$23.62 /

+1.18 (+5.26%)

  • 23
    Jan
MRK Merck
$80.26 /

+1.21 (+1.53%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

ELAN Elanco
$23.62 /

+1.18 (+5.26%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

ELAN Elanco
$23.62 /

+1.18 (+5.26%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.